#United States #AI Drug Discovery #Palo Alto, California #Transcripta Bio #Microsoft Research

Transcripta Bio and Microsoft Collaboration

In a groundbreaking move in the realm of biotechnology, Transcripta Bio has officially entered into a research partnership with Microsoft Research. Announced on May 30, 2025, this collaboration aims to pioneer the use of artificial intelligence (AI) in the quest for understanding and discovering disease-gene associations. The objective is to streamline and accelerate the discovery process for potential therapies, particularly focusing on rare diseases.

Transcripta Bio is renowned for its proprietary Drug-Gene Atlas, an immense database containing over one billion gene responses coupled with comprehensive transcriptome data. The wealth of information stored in this atlas is combined with Microsoft's advanced machine learning prowess to create a robust platform for identifying novel therapeutic opportunities. The goal? To facilitate faster and more reliable identification of potential drug candidates compared to traditional methods, which may be slower or less accurate.

The collaboration will focus on the analysis of chemotranscriptomic datasets. Both teams aim to pinpoint candidate disease-gene associations confirmed by solid experimental evidence of gene expression modulation. This approach could potentially revolutionize the current methodologies used in drug discovery by allowing for quicker transitions from initial discovery phases to clinical candidate selection.

Scott Saponas, who serves as the Senior Director and Deputy Lab Director at Microsoft Research Health Futures, expressed enthusiasm about the partnership, stating, “We are excited to collaborate with Transcripta Bio to leverage our expertise in rare disease genomics and AI. Our aim is to develop innovative methods for drug discovery that can significantly impact the treatment of rare diseases.” This reflects a significant commitment from leading tech and biotech firms to push the boundaries of what's possible in medicine.

Dr. Chris Moxham, the Co-founder and CEO of Transcripta Bio, reinforced this message by remarking, “This collaboration with Microsoft Research enables us to scale our transcriptomics-driven approach, leveraging Microsoft's computational resources and AI expertise. Together, we are setting a new standard for the speed, certainty, and efficiency of drug discovery.” This highlights the critical synergy that arises when technology and biological research intersect.

In essence, the partnership is seeking to make strides towards reducing the time it takes for scientific discoveries to reach patients. By accelerating the pathways that lead from academic research to real-world applications, there is a growing potential for bringing new therapies to market much more efficiently than has been customary in the life sciences sector.

This collaboration underlines a trend in healthcare technology where big data and AI are being leaned upon to deliver innovative healthcare solutions. As the capabilities of AI continue to expand, its role in identifying and validating candidate therapeutics could become a cornerstone of modern drug development.

About Transcripta Bio
Transcripta Bio stands at the forefront of AI-driven drug discovery, specializing in leveraging transcriptomics for therapeutic insights across various disease states. Through its unique AI platform, the company is accelerating the discovery and validation processes for promising new drug candidates while utilizing both repurposed pharmaceuticals and innovative molecules for specific therapeutic targets.

To learn more about Transcripta Bio and its cutting-edge approach to drug discovery, visit www.transcriptabio.com.